Pharmacological approaches with diazoxide or the somatostatin analogue octreotide-LAR to suppress insulin secretion in humans, also support the view that hyperinsulinemia may have more of a primary role in MetS [151,152]. The gene discussed is INS; the disease is metabolic syndrome.